Literature DB >> 15957516

The Goldman Consensus statement on depression in multiple sclerosis.

.   

Abstract

BACKGROUND: In January 2002 the New York City Chapter of the National Multiple Sclerosis Society convened a panel of experts to review the issue of depressive affective disorders associated with multiple sclerosis (MS). This Consensus Conference was supported by a grant from the Goldman family of New York City.
RESULTS: The panel reviewed summaries of current epidemiologic, neurobiologic, and therapeutic studies having to do with depressive disorders among MS patient populations. Depressive disorders occur at high rates among patients with MS, and there is reason to believe that the immunopathology of the disease is involved in the clinical expression of affective disorders. The depressive syndromes of MS have a major, negative impact on quality of life for MS sufferers, but are treatable. At the present time, most MS patients with depression do not receive adequate recognition and treatment.
CONCLUSIONS: The Goldman Consensus Conference Study Group provides recommendations for improved screening, diagnosis, and clinical management for depressive affective disorders among patients suffering from MS.

Entities:  

Mesh:

Year:  2005        PMID: 15957516     DOI: 10.1191/1352458505ms1162oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  71 in total

1.  Treatment of mood disorders in multiple sclerosis.

Authors:  Luis Pintor Pérez; Roberto Sánchez González; Eva Baillés Lázaro
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

2.  Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.

Authors:  Stefan M Gold; Kyle C Kern; Mary-Frances O'Connor; Michael J Montag; Aileen Kim; Ye S Yoo; Barbara S Giesser; Nancy L Sicotte
Journal:  Biol Psychiatry       Date:  2010-06-19       Impact factor: 13.382

3.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

4.  Depression in multiple sclerosis: a longitudinal analysis.

Authors:  Claudia C Beal; Alexa K Stuifbergen; Adama Brown
Journal:  Arch Psychiatr Nurs       Date:  2007-08       Impact factor: 2.218

5.  Prescribed psychiatric medication among multiple sclerosis patients before and after disability pension: a register study with matched controls.

Authors:  Philip Brenner; Ellenor Mittendorfer-Rutz; Jussi Jokinen; Kristina Alexanderson; Jan Hillert; Petter Tinghög
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-05-11       Impact factor: 4.328

6.  A tutorial on structural equation modeling for analysis of overlapping symptoms in co-occurring conditions using MPlus.

Authors:  Douglas D Gunzler; Nathan Morris
Journal:  Stat Med       Date:  2015-06-04       Impact factor: 2.373

7.  Depression levels and interferon treatment in people with multiple sclerosis.

Authors:  Sonya Kim; Frederick W Foley; Mary Ann Picone; June Halper; Vance Zemon
Journal:  Int J MS Care       Date:  2012

8.  Prevalence and predictors of depression in Iranian patients with multiple sclerosis: a population-based study.

Authors:  Seyed Mohammad Seyed Saadat; Mozaffar Hosseininezhad; Babak Bakhshayesh; Seyedeh Nastaran Seyed Saadat; Seyedeh Parand Nabizadeh
Journal:  Neurol Sci       Date:  2013-12-10       Impact factor: 3.307

Review 9.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

10.  Variations in functioning and disability in multiple sclerosis. A two-year prospective study.

Authors:  Charlotte Ytterberg; Sverker Johansson; Magnus Andersson; Lotta Widén Holmqvist; Lena von Koch
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.